The therapeutic approach was safe, but the study did not meet its primary efficacy outcome using the six-minute walking test.

At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Abbott (ABT) announced late-breaking data from its Triluminate Pivotal trial that show the TriClip transcatheter edge-to-edge repair system to ...

Discover why suture-based closure may be safer for TAVI patients. Learn more about this large registry analysis.